---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-045098"
form_type: "8-K/A"
ticker: "ADTX"
cik: "0001726711"
company_name: "Aditxt, Inc."
filed_at: "2025-05-19T23:59:59+00:00"
generated_at: "2026-05-21T01:52:13.525379+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aditxt files amendment with Evofem Q1 results; merger deadline extended to Sep 30, 2025

## Summary
- Evofem Q1 2025 product sales net $845K, down 77% YoY from $3.6M; net income of $956K vs net loss $4.8M.
- Fifth Amendment to merger agreement moves required close to Sep 30, 2025; Aditxt to invest $1.5M in April 2025.
- Aditxt terminated Appili Therapeutics arrangement agreement effective May 31, 2025; removed from pro forma.
- Evofem had working capital deficit of $65M, accumulated deficit $896.7M, and substantial doubt as going concern.
- Evofem common stock moved from OTCQB to OTC Pink in April 2025 after failing minimum bid price compliance.

## SEC filing metadata
- accession: 0001213900-25-045098
- form_type: 8-K/A
- ticker: ADTX
- cik: 0001726711
- company_name: Aditxt, Inc.
- filed_at: 2025-05-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726711/000121390025045098/0001213900-25-045098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726711/000121390025045098/ea0242647-8ka5_aditxt.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-045098
- JSON: https://secwatch.observer/filing/0001213900-25-045098.json
- Plain text: https://secwatch.observer/filing/0001213900-25-045098.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.